Clinical Trials Logo

Macular Degeneration clinical trials

View clinical trials related to Macular Degeneration.

Filter by:

NCT ID: NCT05381948 Active, not recruiting - Clinical trials for Wet Age-related Macular Degeneration

Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)

DAVIO2
Start date: July 28, 2022
Phase: Phase 2
Study type: Interventional

This is a phase 2 randomized, double -masked study comparing the efficacy of EYP-1901 at two dose levels: 2060 ug and 3090 ug against Aflibercept.

NCT ID: NCT05380492 Active, not recruiting - Clinical trials for Age-related Macular Degeneration

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

Start date: November 17, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This safety study comprises a dose escalation study of VOY-101, followed by a cohort of subjects randomized to the maximum tolerated dose arm, a lower dose arm, and control arm.

NCT ID: NCT05265624 Active, not recruiting - Clinical trials for Age-Related Macular Degeneration

The Moran AMD Genetic Testing Assessment Study

MAGENTA
Start date: August 3, 2022
Phase: Phase 2
Study type: Interventional

The goals of this study are: To assess the impact of genetic testing for Age-related Macular Degeneration (AMD) on lifestyle behaviors as measured by systemic and ocular carotenoid status.

NCT ID: NCT05244304 Active, not recruiting - Stargardt Disease 1 Clinical Trials

Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Stargardt Disease

DRAGON
Start date: March 28, 2022
Phase: Phase 3
Study type: Interventional

The primary objective of this trial is to assesses the efficacy of tinlarebant in slowing the rate of growth of atrophic lesion(s) in adolescent subjects with STGD1

NCT ID: NCT05220085 Active, not recruiting - Clinical trials for Age-Related Macular Degeneration

Beovu Experience UZ Leuven

BEL
Start date: December 1, 2020
Phase:
Study type: Observational

Reporting early real-world clinical data of consecutive patients on the use of Beovu® (brolucizumab) intravitreal injections in patients with neovascular age-related macular degeneration.

NCT ID: NCT05155293 Active, not recruiting - Clinical trials for Neovascular (Wet) AMD

Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE)

ALVOEYE
Start date: June 28, 2022
Phase: Phase 3
Study type: Interventional

This is a randomized, double-masked, parallel-group, multicenter, therapeutic equivalence study evaluating the efficacy, safety, and immunogenicity of AVT06 compared with Eylea in subjects with neovascular (wet) AMD.

NCT ID: NCT05112861 Active, not recruiting - Clinical trials for Diabetic Macular Edema

A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders

NORSE SEVEN
Start date: November 15, 2021
Phase: Phase 3
Study type: Interventional

The study will compare the safety of ophthalmic bevacizumab in vials versus pre-filled syringes in subjects diagnosed with a retinal condition that would benefit from treatment with intravitreal injection of bevacizumab, including: exudative age-related macular degeneration, diabetic macular edema, or branch retinal vein occlusion.

NCT ID: NCT05064865 Active, not recruiting - Clinical trials for Age-related Macular Degeneration

Impact of Regular Consumption of Grapes on Eye Health in Singapore Older Adults

Start date: January 28, 2022
Phase: N/A
Study type: Interventional

Aging epidemics in Singapore are rapidly increasing and Age-related macular degeneration (AMD) prevalence is significantly associated with older age. This study aims to understand the effect of consuming freeze-dried table grape powder on AMD in an older population.

NCT ID: NCT05019521 Active, not recruiting - Geographic Atrophy Clinical Trials

A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Start date: August 23, 2021
Phase: Phase 2
Study type: Interventional

This is a dose finding study designed to evaluate the efficacy, safety, and pharmacokinetics of danicopan in participants with GA secondary to AMD. The study consists of a Screening Period of up to 6 weeks, a 104-week masked Treatment Period, followed by a 30-day Follow-up after the last dose. This study will have 4 treatments arms: 100 milligrams (mg) twice daily (bid), 200 mg bid, 400 mg once daily (qd), and matching placebo.

NCT ID: NCT05005884 Active, not recruiting - Clinical trials for Age Related Macular Degeneration

Possible Effects of Supplement Therapy With Oral Phenolics on Cluster of Differentiation 163 (CD-163) Biomarker of Patients With Age-related Macular Degeneration

Start date: July 28, 2021
Phase: Phase 1
Study type: Interventional

In this multi-center study, possible effects of supplement treatment with oral phenolics on plasma CD-163 and progression of dry and wet age-related macular degeneration (AMD) via evaluating the CD163 before and after the prescription of this drug will be evaluated in patients with dry type AMD and Neo vascular age-related macular degeneration (nAMD). Both AMD subgroups will be recruited. In terms of evaluation of the effects of phenolics (500 mg caplets/day) on AMD progression, patients will be randomized and divided into 2 subgroups i.e. (i) receiving phenolics supplementation; and, (ii) receiving placebo for 1 month. The phenolics/placebo caplets will resemble completely and be encoded at origin; Neither the participants nor the researchers will be informed about the codes until the end of the study.